OPTHEA LIMITED ORDINARY (OPT) Short Interest
OPTHEA LIMITED ORDINARY (ASX:OPT) had 1.93% of shares reported as short positions as of 16 May 2026, representing 26,386,084 shares. OPTHEA LIMITED ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
- Short interest
- 1.93%
- Reported positions
- 26,386,084
- Industry
- Pharmaceuticals, Biotechnology & Life Sciences
- As of
- 16 May 2026
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
OPT
Opthea
Opthea is a biopharmaceutical company focused on developing innovative biologics-based therapies for treating vision-threatening eye diseases. The company is pioneering the development of sozinibercept, a first-in-class VEGF-C/D 'trap' inhibitor, aimed at improving treatment outcomes for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).